SEC Filing Summary: Form 13F-HR
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Takeda Pharmaceutical Co Ltd, an institutional investment manager based in Tokyo, Japan. The report covers the calendar quarter ended December 31, 2023. The filing was signed by Amit Singh, Senior Vice President and Head of Treasury, on February 13, 2025.
Key Financial Metrics
As a Form 13F filing, this document reports equity holdings rather than the company's operational financial performance. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity for Takeda Pharmaceutical Co Ltd is not present in this text.
- Total Value of Reported Holdings: $327,499,882
- Total Number of Holdings Entries: 16
- Other Included Managers: 1 (Takeda Vaccines, Inc.)
Material Changes
The filing text does not provide comparative data for the prior period; therefore, material changes in holdings value or composition cannot be determined from this summary alone.
Guidance, Outlook, and Risks
This form is a regulatory disclosure of securities holdings and does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Investor Verification Checklist
- Verify the specific 16 equity positions held by Takeda Pharmaceutical Co Ltd to understand their investment strategy.
- Confirm the inclusion of "Takeda Vaccines, Inc." as an other included manager under file number 028-24939.
- Note that this filing reflects holdings as of December 31, 2023, and does not represent Takeda's own corporate financial health.
- Check for subsequent amendments or updated filings for the 2024 reporting periods.